Slim Now TN provides a useful example of the difference between documenting a service and demonstrating its results. Its website names semaglutide and tirzepatide, identifies a Murfreesboro office, offers Tennessee telehealth visits and publishes monthly prices. Those details establish an advertised GLP-1 weight-management offering. They do not establish which exact products patients receive, how those products relate to published clinical trials or what outcomes this practice achieves. For a prospective patient, the central evidence question is not simply whether these ingredient names have been studied, but whether the proposed treatment is clearly identified.
This review examines public documentation consulted October 19, 2026, rather than firsthand treatment or independently verified clinical performance. Slim Now TN supplies more concrete pricing and staff information than a bare appointment page, including consultation and follow-up descriptions. However, its general $195 first-month offer does not clearly align with its $85 initial semaglutide listing. The consulted pages also leave the dispensing pharmacy, exact formulations, cancellation terms and remote-start process unresolved. These are specific documentation gaps—not proof that the practice lacks appropriate arrangements or that every patient encounters a problem.
At a glance
- Documented GLP-1 offering
- Slim Now TN advertises semaglutide and tirzepatide, with an office in Murfreesboro and telehealth visits in Tennessee.Sources: [5]
- Published semaglutide prices
- Monthly listings are $85 for 0.25 mg, $125 for 0.50 mg, $200 for 1 mg, $250 for 1.50 mg and $300 for 2 mg; exact products and formulations are not identified.Sources: [5]
- Published tirzepatide prices
- Monthly listings are $195 for 2.5 mg, $295 for 5 mg, $395 for 7.5 mg and $495 for 10 mg; the site says prices increase with dosage increases.Sources: [5]
- Unreconciled introductory offer
- A general first-month offer is $195, while the initial semaglutide listing is $85 per month with an initial consultation. The consulted pages do not explain the difference.Sources: [5]
- Product evidence limitation
- The consulted documentation does not identify the dispensing pharmacy or establish whether the specific products supplied are FDA-approved or compounded.Sources: [5]
Start with the product, not the ingredient name
Slim Now TN explicitly advertises both semaglutide and tirzepatide. Its general explanation describes injections going under the skin, but the consulted documentation does not identify a brand, manufacturer, exact formulation or dispensing pharmacy. A “Pharmacy Partner” link appears, yet its destination content was not available in the consulted material. The published milligram labels therefore identify advertised pricing options, not a complete product specification, concentration, container size or verified monthly quantity.
That distinction limits what an evidence review can conclude. FDA approval belongs to a specific drug product, not to a clinic or pharmacy. The documentation does not establish whether Slim Now TN supplies approved products, compounded preparations or different arrangements for different patients. It would be equally unsupported to call its products FDA-approved or to label them compounded solely because the website omits brand names. Our guide to approved medicines and compounded preparations explains why these are separate evidence questions.
If a proposed product is compounded, FDA says such preparations are not FDA approved and do not undergo its premarket review for safety, effectiveness and quality. FDA recommends compounded drugs when an individual's medical needs cannot be met by an approved drug, with a prescription and a state-licensed pharmacy. Nonapproval alone does not prove clinical inequivalence. For this practice, the immediate task is identifying the actual prescription and pharmacy before trying to apply broader clinical findings.
What the price schedule actually documents
Slim Now TN publishes a tiered monthly schedule rather than one uniform program price. Semaglutide runs from the listed 0.25 mg option at $85 per month to the listed 2 mg option at $300; tirzepatide runs from 2.5 mg at $195 to 10 mg at $495. These are the website's presentation labels, not dosing recommendations. The table below preserves the advertised amounts without treating milligrams as proof of formulation, concentration, injection frequency or total quantity supplied.
The initial 0.25 mg semaglutide and 2.5 mg tirzepatide options include a provider consultation. Later listed options describe monthly provider checkups and measurement of progress and vital signs. The tables also describe medication for home administration. Separately, the site advertises the first month of “this program” for $195, then says the payment schedule follows. It does not explain why the initial semaglutide table instead says $85. Neither figure should be silently substituted for the other.
The site expressly warns that price increases when dosage increases, so the lowest listing is not a documented ongoing price for every patient. The consulted pages do not specify upfront collection, automatic billing, insurance acceptance, reimbursement, taxes, laboratory coverage or other potential charges. They use monthly language, not a defined four-week interval. A written quote should reconcile the introductory offer with the selected product and clarify the billing period, included services and any separate fees.
| Published category | Advertised monthly prices | Documented inclusion or qualification |
|---|---|---|
| General first-month offer | $195 | Not reconciled with the $85 initial semaglutide listing |
| Semaglutide initial listing | 0.25 mg: $85 | Initial provider consultation and use instructions; first administration described as in-office |
| Other semaglutide listings | 0.50 mg: $125; 1 mg: $200; 1.50 mg: $250; 2 mg: $300 | Monthly checkup, progress measurement and vital signs |
| Tirzepatide initial listing | 2.5 mg: $195 | Initial provider consultation and use instructions; first administration described as in-office |
| Other tirzepatide listings | 5 mg: $295; 7.5 mg: $395; 10 mg: $495 | Monthly checkup, progress measurement and vital signs |
Clinical trials do not measure this practice's performance
The consulted documentation does not establish a Slim Now TN patient-outcome dataset. Its promotional weight-loss statements and comparisons between medications should not be treated as a clinic-specific success rate or proof of superiority. Published drug trials can inform discussions about treatment, but they answer questions about defined study products, populations and protocols. They do not automatically validate every commercial service using the same ingredient name. This matters especially here because the exact products supplied remain unidentified.
STEP 1 studied subcutaneous semaglutide over 68 weeks in adults with obesity, or overweight plus a weight-related condition, without diabetes; both groups received lifestyle intervention. SURMOUNT-1 studied subcutaneous tirzepatide over 72 weeks in adults with obesity, or overweight plus a weight-related complication, excluding diabetes. Gastrointestinal tolerability and treatment discontinuation were relevant in both trials. Novo Nordisk funded STEP 1, and Eli Lilly funded SURMOUNT-1. Neither was a study of Slim Now TN.
The practice's price tiers are not a substitute for matching a proposed product to the actual trial intervention. Trial findings do not establish outcomes for unidentified preparations, different routes, compounded versions or individual patients, and comparing separate trials is not a randomized head-to-head comparison. Our explanations of what STEP 1 can tell readers and how to interpret SURMOUNT-1 provide context without turning research averages into a provider ranking.
The first visit has a remote-care question to resolve
The practice lists its office at 5607 Franklin Rd, Murfreesboro, TN 37128, and expressly offers telehealth visits within Tennessee. The consulted pages do not establish availability in other states. Advertised office hours are Monday through Thursday, 8 a.m. to 5 p.m.; Friday, 8 a.m. to noon; and every other Saturday, 9 a.m. to 2 p.m. Those hours document access to the business, not a promise of immediate clinical responses or after-hours support.
Appointments begin by contacting the office, with a website form, telephone at 615-439-6929 and email at info@slimnowtn.com among the published routes. The site invites consultation with its providers or medical staff; it does not establish guaranteed prescribing or a response deadline. The consulted pages also do not detail minimum age, BMI criteria, required laboratory work or a complete GLP-1 screening process. General medication criteria should not be substituted for this practice's unpublished requirements.
A particularly practical ambiguity is the initial administration. The initial GLP-1 listings describe medication-use instruction and a first dose administered in the office, while the practice also advertises Tennessee telehealth. It does not explain whether remote patients must travel, follow another teaching process or use a different service arrangement. Before scheduling, a prospective telehealth patient should ask how the first visit, teaching and initial administration work together, and whether an in-person appointment is required.
Named clinicians are useful information, not independent verification
Slim Now TN identifies Madison Umbeck as FNP-C, MSCP and describes her as a board-certified family nurse practitioner. It attributes a nursing bachelor's degree from Saint Louis University and a nursing master's degree from Belmont University to her. The site also lists Shelby Turvey as FNP-C, with more than 30 years in health care and a focus on holistic health and well-being. These are provider-published professional descriptions, not credentials independently verified for this review.
J. Seth Weathersby is listed as owner and PA-C—a physician assistant credential, not a physician designation. The site attributes an exercise-science bachelor's degree and a Master of Medicine from Trevecca Nazarene University to him. It also says he serves on Tennessee's state board for physician assistants and has more than 20 years of urgent-care experience. Those statements help identify the advertised team but do not independently establish current licensing, prescribing responsibility or which clinician a patient will see.
The follow-up descriptions are more concrete than a promise of medication alone: later price tiers include a monthly checkup and tracking of progress and vital signs. Still, the pages do not explain who reviews results, handles medication concerns between appointments or coordinates laboratory testing. NIDDK describes follow-up as attention to tolerance and response, not merely renewed payment. Our guide to clinical follow-up beyond renewal explains why named services and a working communication process both matter.
Home administration does not establish a delivery service
The pricing descriptions refer to medication for administration at home. That establishes an advertised home-use component, not a shipping promise. The consulted documentation does not say whether patients collect medication, receive it by mail or use another arrangement. It also does not identify a carrier, shipping charge, dispatch timetable, arrival estimate or refrigeration procedure. A prospective patient therefore cannot infer doorstep delivery simply from the words describing home administration.
The missing pharmacy identity is consequential beyond convenience. It leaves unanswered who dispenses the prescription, provides the final label, explains storage and resolves a damaged or questionable supply. These responsibilities may be divided between the practice and a pharmacy, but the consulted pages do not explain that division. A useful prepayment request is the dispensing pharmacy's name and contact details, the exact product description and written instructions for obtaining help with a supply concern.
FDA advises not using an injectable GLP-1 drug that arrives warm or with insufficient refrigeration, and contacting the provider or dispensing pharmacy to resolve the concern. FDA also reports measuring or administration errors involving compounded medication, some associated with hospitalization. Those reports are not evidence of an incident at Slim Now TN. They explain why patients need clear product-specific instructions from a prescriber or pharmacist rather than trying to derive administration directions from an online price table.
Monthly pricing leaves the ongoing agreement unresolved
A monthly price is not, by itself, a subscription contract or a minimum commitment. The consulted Slim Now TN pages do not publish terms for automatic renewal, cancellation, refunds, prepayment or discounts. That prevents a reliable description of how a patient ends service, whether a notice deadline applies or what happens to a payment after a clinical decision not to prescribe. It does not prove that no terms exist; they may be provided during enrollment.
The practical distinction is between what is advertised and what a patient agrees to pay. Ask for the first charge, later charges, billing dates and applicable cancellation and refund rules in writing. Because the site warns that prices increase with dosage increases, also ask how any proposed price change is communicated and approved. Cancellation and reimbursement are separate questions: being able to stop future service would not establish a right to recover an earlier payment.
Insurance is another unresolved boundary. The consulted pages do not specify accepted plans, insurer reimbursement or coverage for laboratory work. NIDDK notes that some plans cover weight-management medications and others do not; coverage requires confirmation with the plan. Consultation coverage and medication coverage are separate issues. Neither the published monthly table nor the availability of a clinical visit establishes that an insurer will pay, or that the advertised amount represents every expense associated with care.
Separate website privacy and add-on services from GLP-1 care
Slim Now TN's privacy policy describes collecting comment-form information, IP addresses and browser identifiers for spam detection. It says comments and their metadata are retained indefinitely. It also permits requests to erase personal data, subject to administrative, legal and security retention exceptions. These statements concern website data practices; they do not establish a medical-record retention schedule or a complete account of how telehealth consultations and clinical communications are protected.
The consulted material does not include the content behind the HIPAA link or document a clinical patient portal. Generic references to website accounts should not be treated as proof of a secure clinical messaging system. Before sending medical details, ask which intake and communication channels the practice uses and where its clinical privacy notice can be reviewed. Published email and web forms are contact options, but their presence alone does not explain the handling of sensitive health information.
The practice also advertises NAD+, including a 50 mg listing at $50 per month. That is a separate commercial offering, not evidence that NAD+ is included in GLP-1 prices or improves the program's outcomes. Its NAD+ section lists pregnancy or breastfeeding, active cancer, severe liver or kidney failure and known NAD+ allergy as situations in which it says not to take that product. Those statements should not be repurposed as Slim Now TN's GLP-1 eligibility rules.
Questions & answers
Does Slim Now TN offer GLP-1 treatment outside Tennessee?
The website explicitly offers telehealth visits in Tennessee and lists its Murfreesboro office. The consulted documentation does not establish service in other states. It also does not explain whether every Tennessee telehealth patient can start remotely, because initial listings describe first administration in the office. Confirm both geographic eligibility and any travel requirement before booking.
Is the first month $85 or $195?
Both amounts appear: a general first-month program offer is $195, while the 0.25 mg semaglutide listing is $85 per month and includes an initial consultation. The initial 2.5 mg tirzepatide listing is $195 per month. The pages do not reconcile the general offer with the semaglutide table. Request a written, product-specific first-month quote rather than assuming one statement overrides another.
Which pharmacy and exact products does Slim Now TN use?
The consulted documentation does not identify the dispensing pharmacy, manufacturer, brand or exact formulation. A pharmacy-partner link does not resolve those questions without its destination information. Ask for the pharmacy's name and contact details and the proposed prescription's complete identity. The available material does not support labeling the products either FDA-approved or compounded.
What follow-up is included in the monthly listings?
The later semaglutide and tirzepatide tiers describe monthly provider checkups, progress measurement and vital signs. Initial options instead emphasize consultation, medication-use instructions and first administration in the office. The pages do not establish response times between appointments, after-hours support or whether laboratory work carries a separate charge. Ask how these services operate for telehealth patients.
Does medication for home use mean it will be shipped?
No delivery method is established by that wording. Slim Now TN describes home administration but does not document pickup versus shipping, delivery fees or arrival timing. Confirm the fulfillment process and storage instructions before paying. If an injectable GLP-1 shipment arrives warm or inadequately refrigerated, FDA advises not using it and contacting the provider or dispensing pharmacy.
Can I cancel and receive a refund?
The consulted pages do not publish cancellation or refund terms, so neither a cancellation procedure nor a refund entitlement can be confirmed. Monthly pricing alone does not establish automatic renewal or a minimum commitment. Request the enrollment agreement before payment, including notice deadlines, future billing rules and what happens if treatment is not prescribed or is discontinued.
Our assessment
Slim Now TN documents a recognizable Tennessee GLP-1 service: named clinicians, a physical office, telehealth access, tiered medication pricing and described monthly monitoring. Those concrete details make it possible to prepare focused questions rather than relying on a vague promotional promise. They do not establish provider-specific effectiveness, independently verified credentials or the identity and regulatory status of the products supplied. The most consequential next documents are a product-and-pharmacy description, a reconciled first-payment quote, an explanation of remote initiation and written ongoing-service terms. A prospective patient who receives clear answers will have a stronger basis for evaluating the offer. Until then, the public record supports describing an advertised care program, not endorsing its outcomes or assuming that clinical trial results transfer to its unidentified products.
This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.
Sources & documentation
Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.